Portal hypertensive rebleeding in cirrhosis is a more serious disease with many clinical treatments, such as splenic embolization, splenectomy, portal shunt, portal shunt, portal odd shunt, sclerosing agent, ligature, etc., and even liver transplantation, which are traumatic and costly for patients and not easily accepted by many patients in clinical practice. A recent evaluation by British scholars concluded [2]:Non-selective β-blockers are currently the drug of choice for rebleeding prevention and can significantly reduce the risk of rebleeding in compliant patients with portal hypertension. Cardiotrophin is a non-selective β-blocker that slows the heart rate, constricts the vascular bed and reduces cardiac output and portal blood flow, which effectively reduces the pressure in the portal and varicose veins. It also improves local mucosal blood circulation, distributes blood flow to where it is needed more, and alleviates gastric mucosal lesions caused by portal hypertension [5]; however, 20%-30% of those who use the insulin alone still respond poorly to it and experience rebleeding, and the effective index of insulin, hepatic venous pressure gradient (HVPG), there are still difficulties in clinical application, and the change in pulse rate does not correctly reflect the change in portal pressure and there are reports that long-term use will lead to liver ischemia, hypoxia, deterioration of liver function, reduced synthetic urea, increased blood ammonia and other side effects, so in practice the use of efficacy is not ideal, sure. Aminoglutethimide can act antagonistically with aldosterone by competing with protein receptors in the distal convoluted tubule and collecting duct cells, thus reducing aldosterone-induced water and sodium retention. Some studies have shown [7,8] that aminoglutethimide can reduce effective blood volume, cardiac output and hepatic venous pressure gradient (HPVPG), thus reducing portal pressure and odd vein blood flow and alleviating portal shunt, while having no effect on hepatic blood flow; it is also believed that [9] it has the potential to maintain and enhance the portal pressure-lowering effect of insulin. There is a synergistic effect between aminoglutethimide and insulin in pharmacological action, and the combined application is more effective in preventing bleeding. In our group, through the long-term follow-up of 12 months, 18 months and 24 months, we found that the combination of Jinan and Aminostat could significantly reduce the rate of portal hypertensive rebleeding in cirrhosis (P<0.05), by about 15%-20%, compared with the control group (P<0.01). In the follow-up, we also found that long-term use of the drug has no deterioration of liver function, electrolyte disorders and other side effects, and it is convenient and safe to take, even if some patients with cirrhotic portal hypertension rebleeding, the bleeding volume is significantly reduced, and the hemostatic effect is also better and faster, so it can shorten the bleeding time and reduce the cost of treatment. It was also found that some patients had reduced varicose veins and ascites. In this study, it is believed that the combination of insulin and aminoglutethimide is not only inexpensive, with small side effects and easy to take, but also has obvious effect on the prevention and treatment of rebleeding in cirrhotic portal hypertension, which can be used as the first-line clinical drug.